Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Q32 Bio Inc (QTTB)

Q32 Bio Inc (QTTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,527
  • Shares Outstanding, K 12,304
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,730 K
  • EBIT $ -44 M
  • EBITDA $ -43 M
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.06
  • Number of Estimates 1
  • High Estimate -1.06
  • Low Estimate -1.06
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +8.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +60.10%
on 11/20/25
6.37 -52.12%
on 12/01/25
+0.89 (+41.20%)
since 11/14/25
3-Month
1.69 +80.47%
on 09/18/25
6.37 -52.12%
on 12/01/25
+1.24 (+68.51%)
since 09/15/25
52-Week
1.35 +126.77%
on 07/07/25
6.37 -52.12%
on 12/01/25
-0.65 (-17.57%)
since 12/13/24

Most Recent Stories

More News
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.

QTTB : 3.05 (+3.04%)
AKBA : 1.6100 (-3.01%)
Q32 Bio Sells Complement Inhibitor ADX-097

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

AKBA : 1.6100 (-3.01%)
QTTB : 3.05 (+3.04%)
Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease...

AKBA : 1.6100 (-3.01%)
QTTB : 3.05 (+3.04%)
Q32 Bio: Q3 Earnings Snapshot

Q32 Bio: Q3 Earnings Snapshot

QTTB : 3.05 (+3.04%)
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 --

QTTB : 3.05 (+3.04%)
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients --

QTTB : 3.05 (+3.04%)
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia...

QTTB : 3.05 (+3.04%)
Q32 Bio: Q2 Earnings Snapshot

Q32 Bio: Q2 Earnings Snapshot

QTTB : 3.05 (+3.04%)
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 --

QTTB : 3.05 (+3.04%)
Q32 Bio: Q1 Earnings Snapshot

Q32 Bio: Q1 Earnings Snapshot

QTTB : 3.05 (+3.04%)

Business Summary

Q32 Bio Inc. is a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Q32 Bio Inc., formerly known as Homology Medicines Inc., is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 3.58
2nd Resistance Point 3.34
1st Resistance Point 3.20
Last Price 3.05
1st Support Level 2.81
2nd Support Level 2.57
3rd Support Level 2.43

See More

52-Week High 6.37
Fibonacci 61.8% 4.45
Fibonacci 50% 3.86
Fibonacci 38.2% 3.26
Last Price 3.05
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar